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Abstract
We previously identified a hormone sensitive lipase (HSL) promoter variant, 360CsG, which in vitro exhibits 40%
reduced promoter activity. In this study we examined the effect of the 360CsG on glycemic and lipid measures in the
population based Ely study of metabolic function and insulin resistance in 218 middle-aged men and 276 middle-aged
women. Adipose tissue HSL is the rate-limiting step in triglyceride lipolysis, generating free fatty acids for energy utilization.
HSL is also expressed in pancreatic L-cells where its activity therefore may affect insulin secretion. In the women, carriers of
the HSL 360G allele had significantly lower fasting insulin levels (P = 0.0005) and a lower total area under the curve for
insulin during the oral glucose tolerance test (P = 0.005). There was no demonstrable association in men with these measures
of insulin sensitivity but carriers of the 360G allele had significantly lower fasting non-esterified fatty acid (NEFA) levels
(P = 0.025) and higher low density lipoprotein cholesterol levels (P = 0.02) than men who were non-carriers. This study
provides additional evidence for a role for HSL in the development of insulin resistance, from which carriers of the 360G
allele, associated here with markers of insulin sensitivity in women, and with lower NEFA levels in men, might be
protected. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Dyslipidemia and insulin resistance are both fea-
tures of type 2 diabetes, with the increase in free fatty
acid (FFA) £ux stimulating very low density lipopro-
tein production [1] and glucose stimulated insulin
secretion (GSIS) [2], being a unifying factor. Hor-
mone sensitive lipase (HSL), the rate-limiting enzyme
in the intracellular hydrolysis of triglycerides (Tg), is
a major regulator of free fatty acid release and there-
fore plays a central role in the control of FFA £ux.
HSL activity is tightly controlled in the post-absorp-
tive state by catecholamine activation via cAMP-de-
pendent phosphorylation and, in the fed state, by the
dephosphorylation by insulin (reviewed in [3]). Thus
HSL is post-translationally activated to provide
0925-4439 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 0 1 ) 0 0 0 7 6 - X
* Corresponding author. Fax: +44-171-209-6212.
E-mail address: p.talmud@ucl.ac.uk (P.J. Talmud).
BBADIS 62061 21-11-01
Biochimica et Biophysica Acta 1537 (2001) 239^244
www.bba-direct.com
FFAs when energy intake is low, and deactivated
when exogenous sources of energy are available. As
a key enzyme in FFA homeostasis, HSL is a candi-
date gene for insulin resistance.
The coding region of the HSL gene is remarkably
invariant [4,5] and the only reported polymorphic
site, resulting in the R309C substitution, was identi-
¢ed in Japanese [6] and Chinese samples but not in
Caucasians [5]. In a small study in Japanese type 2
diabetics and healthy controls, the C309 allele was
shown to be associated with higher plasma total cho-
lesterol but not plasma Tg or obesity [6]. In addition,
two dinucleotide repeat minisatellites have been used
in population and transmission disequilibrium stud-
ies to examine the association of genetic variation in
HSL with central obesity and type 2 diabetes. Magre
et al. found an association between the intron 6 re-
peat with central obesity and type 2 diabetes [7],
while Klannemark et al., using the intron 7 repeat,
reported a signi¢cant di¡erence in the distribution of
the alleles in centrally obese and type 2 diabetic pa-
tients compared to controls, as well as transmission
disequilibrium in the type 2 diabetic families [4].
These frequency studies implicate HSL in type 2 dia-
betes, without identifying the functional change.
We have reported a CsG change at position 360
in the HSL promoter with the rare allele being asso-
ciated with a 40% reduction in promoter activity in
vitro, which suggests a decrease in HSL gene expres-
sion [5]. This suggested that variation in the tran-
scriptional control of HSL, in addition to the post-
translational regulation of HSL activity, may also
take place. We have now examined the e¡ect of the
360CsG variant on repeat lipid and glycemic mea-
sures taken 4.4 mean years apart, in 494 middle aged
men and women participating in the prospective Ely
study of metabolic precursors of type 2 diabetes [8].
2. Materials and methods
2.1. Sample population and biochemical measures
The Ely study is a prospective population-based
study of the etiology and pathogenesis of insulin re-
sistance and related disorders which has been de-
scribed previously [8]. Brie£y, subjects who were
not known to have type 2 diabetes were randomly
recruited from a sampling frame consisting of all
those aged 40^65 years in the single GP practice in
Ely, Cambridgeshire in April 1990. Overt diabetics
were excluded from the study. 1122 subjects (74%
response rate) agreed to participate and attended
the local surgery after a 10 h fast for a clinical ex-
amination which included a standard 75 g OGTT
(blood drawn at 0, 30 and 120 min), anthropometric
measurements and a dietary and medical question-
naire. Biochemical measures were taken as previously
reported [8,9]. Plasma non-esteri¢ed fatty acids
(NEFA) were determined enzymatically based on
acyl-CoA synthetase activity (Boehringer Mannheim,
Lewes, Sussex, UK) [9]. The cohort was then remea-
sured 4.4 years later, and 937 of the 1071 individuals
who were non-diabetic at the ¢rst sampling under-
went the same evaluation as in 1990^1992. The sam-
ple of individuals initially considered for this analysis
was a random subgroup of 534 individuals who had
complete data at both phases of the Ely study and on
whom a DNA sample was available. In the analysis
we restricted attention to the 494 individuals who
were non-diabetic and who were not receiving phar-
maceutical therapy for dyslipidemia at any stage dur-
ing this 4.4 year period.
2.2. Polymorphism detection
Detection of the HSL 360CsG polymorphism
by PCR and enzyme digestion has been previously
reported [5].
2.3. Statistical analysis
The data presented utilized both measurements
during this study with an average of 4.4 years be-
tween repeated measures. We hypothesized that a
gene e¡ect would determine the ‘usual’ level of insu-
lin sensitivity, which is a latent or unmeasurable var-
iable. However, it can be estimated by repeated mea-
surement. In this study, therefore, the primary
outcome variable was the repeated measurement of
fasting insulin and area under the curve (AUC) for
insulin following an oral glucose tolerance test. We
did not hypothesize that the HSL polymorphism
would a¡ect the rate of change of these variables
over time. Such an analysis would probably require
longer follow-up in a larger population with more
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precise measurement of insulin sensitivity. This study
was not powered to examine the genotypic e¡ects on
type 2 diabetes.
One way to display the repeated measures is sim-
ply to average them over the two repeats within an
individual. Table 1 shows the means of these aver-
aged data by carrier/non-carrier status strati¢ed by
sex. Comparison between carriers and non-carriers
was by t-test. Traits that were not normally distrib-
uted, e.g. plasma insulin, Tg and related measures,
were normalized after log transformation and geo-
metric means used as the measure of central ten-
dency.
An alternative way of describing the association
between the genetic polymorphism and the repeated
measures of the outcome variables (fasting insulin
and AUC insulin) used a mixed model (SAS V.8,
SAS Institute, Cary, NC, USA). For this a series
of multivariate regression models were undertaken
to describe the e¡ects of genotype on quantitative
phenotypic outcome using the mixed model ap-
proach. This allows time varying (e.g. body mass
Table 1
The unadjusted means by using average values for variables that vary over time, in the men and women
Men Women
WT (193 CC) Rare allele carriers
(23C/G+2GG)
WT (252 CC) Rare allele carriers
(24C/G)
mean S.E. or 95% CI mean S.E. or 95% CI mean S.E. or 95% CI mean S.E. or 95% CI
Age (years) 56.6 0.56 55.1 1.54 55.0 0.47 54.4 1.52
Body mass index (kg/m2) 26.28 0.20 26.3 0.60 26.0 0.30 25.6 0.89
Waist to hip ratio 0.934 0.004 0.920 0.01 0.785 0.004 0.765 0.01
Fasting insulin (pmol/l)a 42.69 (39.60, 46.02) 42.40 (34.35, 52.34) 42.46 (39.75, 45.36) 30.93 (27.11, 35.30)c
30 min insulin incrementa 27.00 (24.54, 29.71) 27.15 (21.47, 34.34) 31.80 (29.43,34.36) 27.28 (21.82, 34.12)
Insulin AUC (pmolWh/l)a 481.5 (444.9, 521.0) 491.7 (396.4, 609.9) 504.3 (473.8, 536.9) 408.1 (340.2, 489.6)b
Fasting NEFA (mmol/l) 0.44 0.013 0.35 0.026b 0.54 0.014 0.53 0.036
NEFA 120 min (mmol/l) 0.086 0.003 0.084 0.010 0.073 0.002 0.065 0.006
Cholesterol (mmol/l) 6.19 0.07 6.52 0.16 6.43 0.07 6.29 0.24
LDL cholesterol (mmol/l) 4.23 0.06 4.59 0.16 4.284 0.07 4.12 0.20
Triglycerides (mmolWh/l)a 1.33 (1.25, 1.41) 1.54 (1.20, 1.96) 1.15 (1.08, 1.21) 1.15 (0.99, 1.34)
Mean (S.E.) or ageometric mean (95% CI); bP6 0.05; cP6 0.01.
Table 2
L coe⁄cients from the regression models for the e¡ect of HSL 360CsG genotype for fasting insulin, 30 min insulin and AUC for
insulin measures after the OGTT and for fasting triglycerides, cholesterol, NEFA and LDL cholesterol (baseline group HSL 360CC)
Men (n = 218) Women (n = 276)
L coe⁄cient S.E. P-value L coe⁄cient S.E. P-value
BMI (kg/m2) 0.298 0.45 0.51 30.266 0.735 0.72
Waist to hip ratioa 30.007 0.01 0.49 30.020 0.01 0.05
Log fasting insulinb (pmol/l) 30.034 0.09 0.70 30.281 0.080 0.0005
Log 30 min insulinb (pmol/l) 30.131 0.11 0.22 30.179 0.11 0.1025
Log insulin AUCb (pmol/l/h) 30.045 0.09 0.60 30.210 0.07 0.0054
Fasting NEFAb (mmol/l) 30.073 0.03 0.0251 0.014 0.036 0.70
120 min NEFAb (mmol/l) 30.003 0.01 0.80 30.007 0.007 0.30
Cholesterolb (mmol/l) 0.313 0.16 0.051 30.118 0.18 0.50
LDL cholesterolb (mmol/l) 0.351 0.15 0.020 30.15 0.16 0.33
Log triglyceridesb (mmol/l) 0.078 0.07 0.28 0.011 0.07 0.87
aAdjusted for age, BMI and smoking status.
bAdjusted for age and smoking status.
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index) and ¢xed covariates (e.g. sex) to be considered
in the same model as independent variables and al-
lows repeat measures of quantitative outcome to be
used as the dependent variable.
3. Results
As presented in Table 1, among the women there
were 252 360CC homozygotes and 24 360C/G het-
erozygotes. There were no women homozygous for
the rare allele. In the men there were 193 360CC
homozygotes, 23 360C/G heterozygotes and two
rare allele 360G/G homozygous individuals. Geno-
typic proportions were in Hardy^Weinberg equilibri-
um with the frequency of the rare 360G allele being
0.06. Table 1 shows the crude data comparing car-
riers and non-carriers for anthropometric and bio-
chemical parameters. In the men the two individuals
who were homozygous for the rare allele were com-
bined with heterozygotes in the analyses. However,
when these two men were removed from subsequent
analyses there was no di¡erence in the outcome (data
not shown). In women, fasting insulin (P6 0.01) and
Fig. 1. Insulin response after the OGTT in women (A) and men (B) participating in the Ely study, according to HSL 360CsG
genotype.
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AUC insulin concentration (P6 0.05) were signi¢-
cantly lower in heterozygous carriers of the 360G
allele than in non-carriers. No such associations
were demonstrable in men. In men, however, the
fasting NEFA concentration was signi¢cantly lower
in carriers (360C/G+GG) than in non-carriers
(360CC) (P6 0.05). These crude data do not take
into account potential confounding factors and
therefore we undertook the more complicated mixed
model regression analysis in order to allow for the
inclusion of time varying covariates such as obesity
and cigarette smoking. Results from the regression
analyses are presented in Table 2. In the women
(n = 279), compared to those homozygous for the
common 360C allele (360 CC), carriers of the
360G allele (360 CG) had lower fasting insulin
(P = 0.0005), and an enhanced response to an oral
glucose tolerance test as re£ected in the lower area
under the curve for insulin (P = 0.005). The adjusted
mean insulin concentration at the di¡erent time
points during the oral glucose tolerance test strati¢ed
by genotype are shown in Fig. 1. In addition, the
waist^hip ratio in those women who were carriers
of the 360G was lower than in the 360C homozy-
gotes, but the di¡erence was only of borderline sig-
ni¢cance (P = 0.05). Although the same trend of as-
sociation was observed in men (n = 218), the
di¡erences between genotype were not statistically
di¡erent. However, those men who were carriers of
the 360CsG variant had signi¢cantly lower fasting
NEFA levels (P = 0.025). Low density lipoprotein
(LDL) cholesterol levels were higher in men who
were 360G carriers compared to CC homozygotes
(P = 0.02) (Table 2), but these di¡erences were not
seen in women.
4. Discussion
This study demonstrates that women who are ho-
mozygous for the common HSL 360C allele tend to
have higher fasting insulin concentrations and an
exaggerated insulin response to a glucose challenge,
both markers for insulin resistance. As insulin resis-
tance is a metabolic precursor of type 2 diabetes,
these data suggest that the rare 360G allele may
be protective. Although the direction of association
was similar in men, the size of the e¡ect was smaller
and was not statistically signi¢cant. These results are
in agreement with those of Pihlajamaki et al. [10],
who recently reported an association between the
HSL 360CsG and insulin stimulated whole body
glucose uptake, suggesting that the 360G allele was
protective of insulin resistance in men. In our study,
however, in men the rare allele of the HSL
360CsG was associated with lowered fasting
NEFA levels, which have been shown previously to
be associated with other features of the insulin resis-
tance syndrome, and which di¡er markedly between
the sexes [9].
The control of HSL gene expression is under at
least two di¡erent promoters. The testis-speci¢c pro-
moter controls HSL expression in the seminiferous
tubules and produces a transcript that has the addi-
tion of a testis-speci¢c exon [11]. Expression of HSL
in all other tissues [12] appears to be directed by the
adipose tissue promoter. Post-translationally con-
trolled by catecholamines and insulin the expression
of HSL in adipose tissue varies according to the type
of adipose tissue, and is dependent upon the expres-
sion of K- and L-adrenoceptors [13]. Thus HSL ac-
tivity di¡ers in subcutaneous fat compared to visceral
or ormental fat [14,15]. In smooth and cardiac
muscle HSL lipolysis of triglycerides provides FFA
energy via L-oxidation [16,17].
The balance between the usage of glucose and
FFA as energy sources (the Randle hypothesis [18])
highlights the fact that raised FFA can impair glu-
cose metabolism and alter insulin sensitivity [19,20].
Thus while insulin is involved in the control of HSL
activity, this study suggests the intriguing possibility
that HSL is itself determining insulin levels. Fatty
acids enhance GSIS within the pancreatic L-cells (re-
viewed in [21]). It was recently reported that HSL is
expressed and active in the L-cells [22] and this raises
the possibility that HSL may mobilize FFA from
intracellular Tg stores in the L-cells. While on the
one hand HSL activity is controlled by insulin, it
may itself contribute to the control of insulin secre-
tion by generating long-chain FFA that participate
in the signaling process in GSIS in addition to the
FFA £ux from adipose tissue activity [2]. However,
to date these is no evidence that the HSL adipose
tissue promoter is active in the pancreatic L-cells.
Thus this interpretation is speculative and needs to
be rati¢ed experimentally.
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Whether the 360CsG variant is indeed the func-
tional change leading to these associations or is in
allelic association with a yet unidenti¢ed functional
site, needs further study. We have evidence (unpub-
lished data, Talmud and Palmen) that there is no
allelic association between this promoter variant
and the intron 6 or intron 7 CA repeats. Since
both variable repeat sequences have been found to
be associated with obesity and type 2 diabetes, this
strengthens the argument that variation in the HSL
gene, as identi¢ed by these three sites, is involved in
the pathophysiology of insulin resistance and thus a
precursor to type 2 diabetes. Results from our study
suggest that the major impact of genetic variation in
HSL is indeed on insulin metabolism and not on
total body fat.
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